Skip to main content
Top
Published in: Clinical and Experimental Nephrology 6/2015

01-12-2015 | Original Article

Effect of cinacalcet cessation on hyperparathyroidism in kidney transcaplant patients after long-term dialysis therapy

Authors: Kentaro Nakai, Hideki Fujii, Mikiko Yoshikawa, Keiji Kono, Yuriko Yonekura, Shunsuke Goto, Takeshi Ishimura, Masashi Takeda, Masato Fujisawa, Shinichi Nishi

Published in: Clinical and Experimental Nephrology | Issue 6/2015

Login to get access

Abstract

Background

Cinacalcet is a promising therapy widely used in dialysis patients with hyperparathyroidism resistant to conventional therapy. However, reports regarding the influence of cinacalcet cessation after long-term use on kidney transplantation patients are few.

Methods

This retrospective observational study included 40 dialysis patients who underwent kidney transplantation. Creatinine, corrected calcium, phosphorus, alkaline phosphatase, and intact parathyroid hormone levels were assessed before and after kidney transplantation according to pretransplant treatment of chronic kidney disease–mineral and bone disorder.

Results

Ultrasonography revealed enlargement of the parathyroid in all patients treated with cinacalcet. Although the data at the time of kidney transplantation were comparable, the serum levels of calcium, alkaline phosphatase, and intact parathyroid hormone after kidney transplantation were higher in patients treated with cinacalcet than in those treated without. However, serum phosphate levels in the cinacalcet group were slightly higher at the time of kidney transplantation and significantly lower 3 months later.

Conclusions

Mineral abnormalities persisted in kidney transplant patients with enlarged parathyroid glands after discontinuation of cinacalcet treatment. Parathyroidectomy should be considered in kidney transplant candidates with the risk of developing refractory hyperparathyroidism after transplantation.
Literature
1.
go back to reference Bonarek H, Merville P, Bonarek M, et al. Reduced parathyroid functional mass after successful kidney transplantation. Kidney Int. 1999;56:642–9.CrossRefPubMed Bonarek H, Merville P, Bonarek M, et al. Reduced parathyroid functional mass after successful kidney transplantation. Kidney Int. 1999;56:642–9.CrossRefPubMed
2.
go back to reference Kawarazaki H, Shibagaki Y, Fukumoto S, et al. Natural history of mineral and bone disorders after living-donor kidney transplantation: a 1-year prospective observational study. Ther Apher Dial. 2011;15:481–7.CrossRefPubMed Kawarazaki H, Shibagaki Y, Fukumoto S, et al. Natural history of mineral and bone disorders after living-donor kidney transplantation: a 1-year prospective observational study. Ther Apher Dial. 2011;15:481–7.CrossRefPubMed
3.
go back to reference Seikrit C, Muhlfeld A, Groene HJ, Floege J. Renal allograft failure in a hyperparathyroid patient following initiation of a calcimimetic. Nat Rev Nephrol. 2011;7:237–41.CrossRefPubMed Seikrit C, Muhlfeld A, Groene HJ, Floege J. Renal allograft failure in a hyperparathyroid patient following initiation of a calcimimetic. Nat Rev Nephrol. 2011;7:237–41.CrossRefPubMed
4.
go back to reference Peng LW, Logan JL, James SH, Scott KM, Lien YH. Cinacalcet-associated graft dysfunction and nephrocalcinosis in a kidney transplant recipient. Am J Med. 2007;120:e7–9.CrossRefPubMed Peng LW, Logan JL, James SH, Scott KM, Lien YH. Cinacalcet-associated graft dysfunction and nephrocalcinosis in a kidney transplant recipient. Am J Med. 2007;120:e7–9.CrossRefPubMed
5.
go back to reference Esposito L, Rostaing L, Gennero I, Mehrenberger M, Durand D, Kamar N. Hypercalciuria induced by a high dose of cinacalcet in a renal-transplant recipient. Clin Nephrol. 2007;68:245–8.CrossRefPubMed Esposito L, Rostaing L, Gennero I, Mehrenberger M, Durand D, Kamar N. Hypercalciuria induced by a high dose of cinacalcet in a renal-transplant recipient. Clin Nephrol. 2007;68:245–8.CrossRefPubMed
6.
go back to reference Evenepoel P, Sprangers B, Lerut E, et al. Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study. Clin Transpl. 2012;26:393–402.CrossRef Evenepoel P, Sprangers B, Lerut E, et al. Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study. Clin Transpl. 2012;26:393–402.CrossRef
7.
go back to reference Jadoul M, Banos A, Zani VJ, Hercz G. The effects of discontinuing cinacalcet at the time of kidney transplantation. NDT Plus. 2010;3:37–41.PubMedCentralPubMed Jadoul M, Banos A, Zani VJ, Hercz G. The effects of discontinuing cinacalcet at the time of kidney transplantation. NDT Plus. 2010;3:37–41.PubMedCentralPubMed
8.
go back to reference Torregrosa JV, Bergua C, Martinez de Osaba MJ, Oppenheimer F, Campistol JM. Evolution of secondary hyperparathyroidism after kidney transplantation in patients receiving cinacalcet on dialysis. Transpl Proc. 2009;41:2396–8.CrossRef Torregrosa JV, Bergua C, Martinez de Osaba MJ, Oppenheimer F, Campistol JM. Evolution of secondary hyperparathyroidism after kidney transplantation in patients receiving cinacalcet on dialysis. Transpl Proc. 2009;41:2396–8.CrossRef
9.
go back to reference Wada M, Furuya Y, Sakiyama J, et al. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest. 1997;100:2977–83.PubMedCentralCrossRefPubMed Wada M, Furuya Y, Sakiyama J, et al. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest. 1997;100:2977–83.PubMedCentralCrossRefPubMed
10.
go back to reference Rodriguez ME, Almaden Y, Canadillas S, et al. The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands. Am J Physiol Ren Physiol. 2007;292:F1390–5.CrossRef Rodriguez ME, Almaden Y, Canadillas S, et al. The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands. Am J Physiol Ren Physiol. 2007;292:F1390–5.CrossRef
11.
go back to reference Tanaka M, Nakanishi S, Komaba H, Itoh K, Matsushita K, Fukagawa M. Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism. NDT Plus. 2008;1:iii49–53.PubMedCentralPubMed Tanaka M, Nakanishi S, Komaba H, Itoh K, Matsushita K, Fukagawa M. Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism. NDT Plus. 2008;1:iii49–53.PubMedCentralPubMed
12.
go back to reference Hirai T, Nakashima A, Takasugi N, Yorioka N. Association of nodular hyperplasia with resistance to cinacalcet therapy for secondary hyperparathyroidism in hemodialysis patients. Ther Apher Dial. 2010;14:577–82.CrossRefPubMed Hirai T, Nakashima A, Takasugi N, Yorioka N. Association of nodular hyperplasia with resistance to cinacalcet therapy for secondary hyperparathyroidism in hemodialysis patients. Ther Apher Dial. 2010;14:577–82.CrossRefPubMed
13.
go back to reference Evenepoel P, Claes K, Kuypers D, Maes B, Bammens B, Vanrenterghem Y. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transpl. 2004;19:1281–7.CrossRef Evenepoel P, Claes K, Kuypers D, Maes B, Bammens B, Vanrenterghem Y. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transpl. 2004;19:1281–7.CrossRef
14.
go back to reference Evenepoel P, Claes K, Kuypers DR, Debruyne F, Vanrenterghem Y. Parathyroidectomy after successful kidney transplantation: a single centre study. Nephrol Dial Transpl. 2007;22:1730–7.CrossRef Evenepoel P, Claes K, Kuypers DR, Debruyne F, Vanrenterghem Y. Parathyroidectomy after successful kidney transplantation: a single centre study. Nephrol Dial Transpl. 2007;22:1730–7.CrossRef
15.
go back to reference Torres A, Lorenzo V, Salido E. Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol. 2002;13:551–8.PubMed Torres A, Lorenzo V, Salido E. Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol. 2002;13:551–8.PubMed
16.
go back to reference Taniguchi M, Tokumoto M, Matsuo D, et al. Persistent hyperparathyroidism in renal allograft recipients: vitamin D receptor, calcium-sensing receptor, and apoptosis. Kidney Int. 2006;70:363–70.CrossRefPubMed Taniguchi M, Tokumoto M, Matsuo D, et al. Persistent hyperparathyroidism in renal allograft recipients: vitamin D receptor, calcium-sensing receptor, and apoptosis. Kidney Int. 2006;70:363–70.CrossRefPubMed
Metadata
Title
Effect of cinacalcet cessation on hyperparathyroidism in kidney transcaplant patients after long-term dialysis therapy
Authors
Kentaro Nakai
Hideki Fujii
Mikiko Yoshikawa
Keiji Kono
Yuriko Yonekura
Shunsuke Goto
Takeshi Ishimura
Masashi Takeda
Masato Fujisawa
Shinichi Nishi
Publication date
01-12-2015
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 6/2015
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-015-1107-1

Other articles of this Issue 6/2015

Clinical and Experimental Nephrology 6/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.